Impact of Impaired Renal Function on the Efficacy and Safety of Second‐Line Tyrosine Kinase Inhibitor Therapy After First‐Line Immuno‐Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study

Documenti analoghi

• Editorial Comment From Dr. Miyake to Effects of Response to First‐Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma
  di: Makito Miyake
  Pubblicazione: (2025)
• Impact of Estimated Glomerular Filtration Rate and Serum C‐Reactive Protein Level to Overall Survival After Second‐Line Targeted Therapy Following Immuno‐Oncology Combination Therapy for Advanced Renal Cell Carcinoma
  di: Keita Nakane, et al.
  Pubblicazione: (2025)
• Editorial Comment to “Clinical Features and Risk Factors of Enfortumab Vedotin‐Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study)”
  di: Makito Miyake
  Pubblicazione: (2026)
• Editorial Comment to Real‐World Outcomes After Radical Cystectomy for Muscle‐Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database
  di: Makito Miyake
  Pubblicazione: (2026)
• Editorial Comment From Dr. Miyake to Effects of Robot‐Assisted Radical Cystectomy on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle‐Invasive Bladder Cancer: A Multicenter Retrospective Study
  di: Makito Miyake
  Pubblicazione: (2025)